Impax Laboratories — J.P. Morgan Healthcare Conference 2012
22 slides from Impax Laboratories's conference presentation, Jan 9, 2012

Slide 1: Improving Health Through Technology
....Improving Health Through Technology J.P. Morgan Healthcare Conference January 9, 2012 Larry Hsu - President & CEO Art Koch - Chief Financial Officer

Slide 2: Safe Harbor Statement
2 Safe Harbor Statement "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of ma

Slide 3: Impax's Dual Strategic Focus
3 Impax's Dual Strategic Focus Unique targeted ANDAs First-to-File, First-to-Market Sustainability through limited competition Difficult to formulate and manufacture 47 apps pending at FDA 46 under development Improve on marketed CNS products Develop IP positions IPX066 NDA filed 4Q11 as 505(b)(2) f

Slide 4: Update on Quality Improvements
Quality Improvements Responded to all warning letter observations Upgraded quality and operations management teams Implemented global Quality Improvement Program Continue to update and communicate with FDA Goal to close out warning letter by end of February 2012 Timing dependent on FDA availability

Slide 5: A Leader in Generic Medicines
....A Leader in Generic Medicines

Slide 6: Generic Growth Initiatives
6 Generic Growth Initiatives

Slide 7: Growing Partnership Portfolio
Growing Partnership Portfolio 7 Supply and commercialization agreement 2 softgel capsule products Development and commercialization agreement 1 nasal spray product 1 topical product Development and supply agreement 2 topical drug products Focusing on Alternative Dosage Forms ....and additional undis

Slide 8: Expanding ANDA Pending Pipeline
8 Expanding ANDA Pending Pipeline 2011 ANDA Filing Goal At least 12 new ANDA applications At least 3 First-to-File or First-to-Market opportunities Results to Date 2008 2009 2010 2011E Non FTF/FTM 6 7 9 7 Potential FTM 2 Potential Shared FTF 2 Potential FTF 2 3 1 1 10 10 10 10(a) (a) Does not reflec

Slide 9: Products Pending or Under Development
9 93 Products Pending or Under Development 44 Currently Marketed ANDAs 46 Under Development ($15 Billion) 47 Pending at FDA ($20 Billion) Present Future Opportunities $35 Billion U.S. Brand/Generic Sales Note: All product sales data included herein are derived from data published by Wolters Kluwer H

Slide 10: Disclosed ANDA Pending Pipeline Offers Growth Opportunities
10 Disclosed ANDA Pending Pipeline Offers Growth Opportunities Disclosed ANDA Pending Pipeline Offers Growth Opportunities Disclosed ANDA Pending Pipeline Offers Growth Opportunities Impax is aware of additional lawsuits containing similar patent infringement claims and believes filers of ANDAs will

Slide 11: Under Development Pipeline
11 Under Development Pipeline Total Under Development 46 $15B * Brands not yet launched or sales data not yet available Unique Targeted High Value ANDAs First-to-File/First-to-Market First-to-File/First-to-Market First-to-File/First-to-Market Focused on: Note: All product sales data included herein

Slide 12: Advancing CNS Treatment
....Advancing CNS Treatment

Slide 13: Brand Growth Initiatives
Brand Growth Initiatives Terma R&D Programs | Collaborations in Pipeline Development & Commercialization Approval and Launch of IPX066 in U.S. In-licensing (products) “Driving to Financial Self-Support” @ MEAN

Slide 14: Phase III Results Support Potential Benefits for Parkinson's Disease Patients
14 Phase III Results Support Potential Benefits for Parkinson's Disease Patients Reduced "Off" time Reduced dosing frequency Increased patient Preference for Treatment Increased "On" time IPX066: Controlled-release Carbidopa/Levodopa IPX066 Improved Motor Symptoms "Data on file, Impax Laboratories"

Slide 15: IPX066: Next Steps in 2012
15 IPX066: Next Steps in 2012 Dec. 2011 Feb./Mar -2012 4Q 2012 Throughout 2012 NDA filed Pre-launch preparation and launch planning Building marketing and sales team Conducting commercial pre-launch activities Expected FDA acceptance of NDA Possible NDA approval

Slide 16: Clinical Stage Pipeline - IPX159
16 Clinical Stage Pipeline - IPX159 IPX159 - Restless Legs Syndrome (RLS) IPX159 Development Overview Product Overview Ex-US compound, NCE US Inhibits uptake of neurotransmitters RLS Market Opportunity US registration path 505(b)(1) - 5 year regulatory exclusivity Significant Commercial Opportunity

Slide 17: IPX159: Development Status
17 IPX159: Development Status Preclinical & POC Phase I Phase IIa Phase IIb - Initiated December 2011 Completed Completed Completed Primary endpoint: International Restless Legs Syndrome Study Group (IRLSSG) Rating Scale Safety and efficacy study North America, randomized, double- blind, placebo-con

Slide 18: 2012 Financial Outlook
2012 Financial Outlook ....Improving Health Through Technology

Slide 19: Healthy Balance Sheet Supports Ongoing M&A
Healthy Balance Sheet Supports Ongoing M&A 19 Significant cash and no debt for investments in growth initiatives

Slide 20: 2012 Financial Outlook
20 2012 Financial Outlook Top-line performance driven generic division products: Variability depending on Generic Adderall XR(r) Supply issues and Shire litigation Citizen Petition status Resolution of warning letter Potential launch of eight generic products Gross margins expected in ~ 47% to 49% r

Slide 21: 2012 Financial Outlook
21 2012 Financial Outlook 2012 Financial Outlook

Slide 22: Strong Platform for Long Term Growth
22 22 Strong Platform for Long Term Growth Unique Targeted High Value ANDAs Offering Long-Term Growth Drivers Generic Brand Drug Delivery Expertise Product Development Formulation Technology Core Competency
Source: SEC EDGAR · 8-K filed Jan 9, 2012
More decks from Impax Laboratories Inc
Q4 2017 Earnings Presentation23 slides · Mar 1, 2018
J.P. Morgan Global Healthcare Conference 201819 slides · Jan 9, 2018
Q3 2017 Earnings Presentation22 slides · Nov 9, 2017
Merger or Acquisition (October 2017)22 slides · Oct 17, 2017
Merger or Acquisition (October 2017)43 slides · Oct 17, 2017
Q2 2017 Earnings Presentation24 slides · Aug 9, 2017